Clinical trials: Antipsychotic Agents
Schizophrenia, Schizoaffective Disorder
Open-label Study of Curcumin C-3 Complex in Schizophrenia
Current evidence suggests that schizophrenia as a serious and complex psychiatric disorder, continues to challenge mental health professionals in their search for better treatment options in the community.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depression
- Trial name
- NCT01875822
- Testing
- Super-Curcumin
- Where
- Puerto Rico
- Volunteers
- 17 people
- Sponsor
- Woodbury, Michel, M.D.
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
The aberrant expression of micro-RNAs (miRNAs) has been described in many human diseases, including schizophrenia (SZ). The previous work has indicated a strong genetic association between the miRNA-30e precursor (pre-miR-30e)…
- Trial name
- NCT02650102
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanxi Medical University
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00658645
- Testing
- Bifeprunox, Quetiapine
- Where
- 38 sites in Bulgaria, China and 6 more
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine
The investigators hypothesis is that an antipsychotic drug combination of low-dose olanzapine plus low-dose trifluoperazine is similar to regular-dose olanzapine monotherapy in efficacy and safety for treatment of…
- Trial name
- NCT02704962
- Testing
- full-dose olanzapine
- Where
- 2 sites in Taiwan
- Volunteers
- 94 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Schizophrenia, Schizoaffective Disorder
Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
This study will provide information regarding dopamine D2/D3 occupancy related with clinical/adverse effects in older people with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00825045
- Testing
- risperidone
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Psychosis
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
The goal of this observational study is to learn about how long-acting injectable antipsychotic (LAIA) medications are affected by the changes that take place in the body during pregnancy, and how much an unborn baby is exposed…
- Conditions
- Schizophrenia, Psychosis, Mania, Pregnancy
- Trial name
- LAMP (NCT05766007)
- Where
- 6 sites in Nigeria
- Volunteers
- 168 people
- Sponsor
- University of Liverpool
Bipolar Disorder, Manic Disorder
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers, in the treatment of manic episodes associated with bipolar…
- Trial name
- NCT00250367
- Testing
- risperidone
- Volunteers
- 151 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Long-term Study of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT01104792
- Testing
- Cariprazine
- Where
- 86 sites in United States, Colombia and 4 more
- Volunteers
- 752 people
- Sponsor
- Forest Laboratories
Bipolar Disorder
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
- Trial name
- PAMS (NCT00746252)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants.
- Trial name
- NCT05712265
- Testing
- Miricorilant, Fluvoxamine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Bexarotene Treatment in Schizophrenia
In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) on severity of psychopathology, cognitive…
- Trial name
- NCT00141947
- Testing
- bexarotene (Targretin)
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Beersheva Mental Health Center
Schizophrenia
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
- Trial name
- NCT01738698
- Testing
- SPD489 40mg, SPD489 100mg, SPD489 160mg
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shire
Psychosis
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.
- Trial name
- NCT00946491
- Testing
- Haloperidol 10 mg Tablets (Cord Laboratories), Haldol 10 mg Tablets (McNeil Pharmaceuticals)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Schizophrenia
Quality of Life in Schizophrenic Patients
This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.
- Trial name
- Quality (NCT00597168)
- Where
- 45 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Schizophrenia
Antipsychotic Induced Structural and Functional Brain Changes
Continuation of antipsychotic drug treatment for at least 12 months after remission of the first psychotic episode represents the gold clinical standard, and it is recommended by all international treatment guidelines.
- Trial name
- APIC (NCT02435095)
- Testing
- Maintenance treatment, Intermittent treatment
- Where
- 11 sites in Germany
- Volunteers
- 174 people
- Sponsor
- RWTH Aachen University
Metabolic Syndrome X
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone.
- Trial name
- NCT00956189
- Testing
- amisulpride, aripiprazole
- Where
- 3 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- National Taiwan University Hospital
First Episode Psychosis
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may…
- Trial name
- NCT00202280
- Testing
- Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- Melbourne Health
Schizophrenia, Schizophreniform Disorders
Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography
Within the schizophrenia population, there are individuals that respond to first-line antipsychotic treatments while others do not.
- Trial name
- NCT06278246
- Testing
- PET Scan
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health